News
Merck expects $200M tariff hit amid Gardasil fallout
The company’s stock fell as much as 2.8% after markets opened in New York Thursday. For the first quarter, Merck’s results beat estimates. First quarter sales were $15.5 billion, above the $15.3 billion analysts had predicted. Adjusted earnings of $2.22 per share outpaced expectations of $2.13 a share.
MSD is also bracing for a $200m hit due to tariffs as it accelerates US manufacturing and shifts its global supply strategy.
Proquad is rarely a newsmaker from Merck’s earnings, but this time around, the U.S. has had a series of measles outbreaks.
Read a preview of Merck below and check back for more analysis soon. Drugmaker Merck reports quarterly results Thursday ...
GARDASIL 9 is a vaccine that helps protect against disease caused by the following types of Human Papillomavirus (HPV): 6, 11, 16, 18, 31, 33, 45, 52 and 58. For more information, see Section 1.
In the last two years, Merck has beaten EPS estimates 88% of the time, and revenue estimates 100% of the time. Meanwhile, ...
SEATTLE — Since its approval by the U.S. Food and Drug Administration in 2006, the HPV vaccine has made considerable strides in preventing cervical and oropharyngeal, or throat cancers.
Cantor Fitzgerald analyst Carter Gould initiated coverage of Merck (MRK) with a Neutral rating and $85 price target Shares have been “a ...
Merck's Q4 results beat expectations, but concerns over Gardasil and Keytruda's patent expirations have weighed on the stock. MRK trades at a depressed valuation with significant EPS growth ...
Merck & Co. Chief Executive Officer Robert Davis was tired of talking about China.On an earnings call in February, he ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback